Accelovance Strengthens Executive Team with Chief Medical Officer

ROCKVILLE, Md., Nov. 14, 2011 /PRNewswire-USNewswire/ -- Accelovance, an award-winning clinical services company, announced today the addition of Stephan A. Bart Sr., M.D. as Chief Medical Officer for the organization.  Dr. Bart will be responsible for medical affairs and site operations, focused on enhancing the level of clinical solutions Accelovance can provide to clients. He joins the executive team with a thorough understanding of clinical operations as a result of previous roles in CRO management and over 15 years in clinical research as a Principal Investigator.

"We are excited to have Dr. Bart join our team in this role with his wealth of operational and medical knowledge.  His background in private practice, site management organizations, Phase I units and CROs align well with Accelovance's comprehensive service offering.  He will support Accelovance's mission to bring greater value to a growing customer base while also strengthening our traditional and innovative services," remarked Steve Trevisan, President and CEO of Accelovance.

Most recently, Dr. Bart held a similar role at Idis, Inc., an expert in named patient programs (NPPs), and at SNBL Clinical Pharmacology Center, a Phase I unit in Baltimore, Maryland.  In addition to protocol development and international regulatory interactions, Dr. Bart has developed and managed teams for Quality Assurance, Medical Information, Medical Affairs, Regulatory Compliance and Study Management.  He is Board Certified in Family Medicine and has a sub-specialty in Women's Health. Dr. Bart began his research in 1984 in a pre-clinical lab and has been active as a clinical physician and researcher for more than 16 years.

"I look forward to working with such a dynamic team that has a different perspective compared to other CROs.  Here is a group who focuses on proactively solving challenges and putting the patient first in strategy development which is relevant to this industry now, more than ever," commented Dr. Bart who has led Phase I-IV clinical research programs in both urgent care and traditional research facilities.  Dr. Bart completed his undergraduate work at the University of Illinois and University of Northeastern Illinois, graduating with a Bachelor of Science in Biology and Chemistry.  He received his Medical Degree from Rush University Medical College and further postgraduate training at the University of Pittsburgh and the University of South Florida. Dr. Bart has held faculty positions at Penn State University as well as the University of Maryland Medical Center.

Headquartered in Rockville, Maryland, Accelovance is a privately held company that has developed a unique operational approach for delivering quality, on time, and cost effective clinical studies.  The Company tailors its offering of full CRO, Clinical Sites, Patient Recruitment, and Call Center to present a clinical solution that meets a Sponsor's needs.  Accelovance's ownership and operation of six (6) research-dedicated clinical sites provides operational insight to study conduct and patient recruitment that other CROs never acquire. Additionally, Accelovance has a wholly owned subsidiary providing regulatory consulting and CRO services in China.  These capabilities can assist clients with global development programs or product registration in China, the fastest growing pharmaceutical market in the world.  

For more information, visit the company's website at http://www.accelovance.com. 

Media Contact:
Garrett D. Smith
Phone: 240.238.4914
[email protected]

SOURCE Accelovance